Reentry Incentives and Support for Engagement With Contingency Management (RISE-CM)

December 23, 2025 updated by: Linda Peng, Oregon Health and Science University

Enhancing Medication for Opioid Use Disorder Retention With Post-Release Contingency Management

People leaving jail face a very high risk of overdose, especially in the first few weeks after release. Staying on medication for opioid use disorder (MOUD) can greatly reduce this risk, but many people stop treatment during this transition. This study is testing whether a program that offers rewards, called contingency management (CM), can help people stay on MOUD after they return to the community.

In this study, people who are taking MOUD in jail can choose to participate. While still incarcerated, they complete one visit where they may receive a small incentive, such as commissary credit or snacks, for enrolling in the CM program. After they leave jail, participants can earn gift cards when they attend their MOUD appointments and counseling sessions.

Participants may take part in the study for up to three months after release. During this time, they can earn up to $600 in incentives based on their treatment engagement. Researchers will also ask participants to complete a baseline survey and a survey at 3 months. We will also review medical records to confirm whether they continued their MOUD.

The researchers want to learn whether this adapted contingency management program is feasible, acceptable to participants, and helpful for supporting treatment engagement after release from jail. The findings will help determine whether this approach should be tested in a larger study to reduce overdose risk and improve health during the post-release period.

Study Overview

Status

Not yet recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

75

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Carol DeFrancesco Senior Research Associate
  • Phone Number: 5033105036
  • Email: defrance@ohsu.edu

Study Contact Backup

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Be adults (age ≥18 years) currently incarcerated at Clatsop County Jail
  • Be enrolled in the jail's MOUD program at the time of recruitment
  • Plan to continue MOUD with Clatsop Behavioral Healthcare upon release
  • Speak English and be able to provide informed consent

Exclusion Criteria

Exclusion Criteria:

  • Are unable to provide informed consent due to cognitive impairment or acute psychiatric instability
  • Are scheduled for transfer to a different facility or geographic location that prevents post-release participation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: RISE-CM Intervention
All participants are enrolled in the intervention arm.
Other: Reentry Incentives and Support for Engagement with Contingency Management (RISE-CM) Intervention
Participants receive gift card rewards for attending MOUD appointments and counseling appointments after release from incarceration.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of patients receiving medication for opioid use disorder
Time Frame: 1, 2, and 3 months
We will assess patient reported receipt of medication for opioid use disorder and also use chart review to determine whether patients are receiving medications and three different time points.
1, 2, and 3 months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of contingency management sessions attended
Time Frame: 3 months
Number of contingency management sessions attended per participant
3 months
Total contingency management rewards earned
Time Frame: 3 months
Total dollar amount of contingency management rewards earned by participant throughout the intervention
3 months
Addiction Severity
Time Frame: Baseline and 3 months
Participant reported addiction severity using the validated Brief Addiction Monitor, a 17-item, multidimensional progress monitoring tool designed to support the provision of measurement-based care to patients commencing and matriculating through treatment for substance use disorders (SUD). The BAM items assess: (1) Risk for relapse or worsening severity of SUD (Range 0-180 with higher scores indicating higher risk), (2) Protective behaviors that support recovery and resistance to relapse (Range 0-180 with higher score indicating higher protective factors), and (3) Use of alcohol and other substances (Range 0-90 with higher score indicating higher substance use).
Baseline and 3 months
Recovery Capital
Time Frame: Baseline and 3 months
Participant reported survey on recovery capital using the validated "Brief Assessment of Recovery Capital (BARC-10)" survey. Score range 10-60 with higher scores indicating higher recovery capital.
Baseline and 3 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Oregon Health and Science University

Collaborators

Oregon Health Authority
Clatsop Behavioral Healthcare
Clatsop County Corrections

Investigators

  • Principal Investigator: Linda Peng, MD, Oregon Health and Science University

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

January 1, 2026

Primary Completion (Estimated)

June 30, 2027

Study Completion (Estimated)

June 30, 2027

Study Registration Dates

First Submitted

December 1, 2025

First Submitted That Met QC Criteria

December 23, 2025

First Posted (Actual)

January 7, 2026

Study Record Updates

Last Update Posted (Actual)

January 7, 2026

Last Update Submitted That Met QC Criteria

December 23, 2025

Last Verified

December 1, 2025

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • STUDY00028902
  • Agreement #184714 (Other Grant/Funding Number: Oregon Health Authority)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Opioid Use Disorder

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kosovo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe